Disclosed herein are compositions (e.g., sprays, paints, etc.) that comprise antimicrobial zeolite nanoparticles. Also provided are hemostatic compositions comprising zeolite nanoparticles, dryer sheets comprising zeolite nanoparticles, and textiles comprising zeolite nanoparticles. Also disclosed are compositions (e.g., sprays) that include a binder polymer to improve coating adherence. In some cases, the zeolite nanoparticles can further comprise an optical tracer (e.g., a fluorophore) associated with the zeolite nanoparticles. The optical tracer can be interrogated to confirm presence of the zeolite nanoparticles (or a coating comprising the zeolite nanoparticles) on a surface. Also provided are methods of forming viricidal coatings using compositions that comprise zeolite nanoparticles dispersed in a carrier.

Disclosed herein are compositions (e.g., sprays, paints, etc.) that comprise antimicrobial zeolite nanoparticles. Also provided are hemostatic compositions comprising zeolite nanoparticles, dryer sheets comprising zeolite nanoparticles, and textiles comprising zeolite nanoparticles. Also disclosed are compositions (e.g., sprays) that include a binder polymer to improve coating adherence. In some cases, the zeolite nanoparticles can further comprise an optical tracer (e.g., a fluorophore) associated with the zeolite nanoparticles. The optical tracer can be interrogated to confirm presence of the zeolite nanoparticles (or a coating comprising the zeolite nanoparticles) on a surface. Also provided are methods of forming viricidal coatings using compositions that comprise zeolite nanoparticles dispersed in a carrier.

The invention provides methods for treating a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a small molecule inhibitor of the PD-1/PD-L1 interaction or a pharmaceutically acceptable salt or prodrug thereof in combination with a therapeutically effective amount of an anti-PD-1 antibody, wherein the small molecule inhibitor of the PD-1/PD-L1 interaction is not a protein.

The invention provides methods for treating a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a small molecule inhibitor of the PD-1/PD-L1 interaction or a pharmaceutically acceptable salt or prodrug thereof in combination with a therapeutically effective amount of an anti-PD-1 antibody, wherein the small molecule inhibitor of the PD-1/PD-L1 interaction is not a protein.

Provided herein are methods of treating cancer (e.g., NSCLC), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) an ILT4 antagonist; and (c) one or more chemotherapeutic agents. Also provided are pharmaceutical compositions and kits containing such agents for the treatment of cancer.

Provided herein are methods of treating cancer (e.g., NSCLC), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) an ILT4 antagonist; and (c) one or more chemotherapeutic agents. Also provided are pharmaceutical compositions and kits containing such agents for the treatment of cancer.

Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and/or reversing, returning blood glucose concentration to a normal level in a diabetic.

Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and/or reversing, returning blood glucose concentration to a normal level in a diabetic.

A composition having cell-derived physiological activity is provided. The composition according to the present invention contains a treated product of megakaryocytes or a culture of the megakaryocytes.

A composition having cell-derived physiological activity is provided. The composition according to the present invention contains a treated product of megakaryocytes or a culture of the megakaryocytes.